drugset / Trial / NCT00724815

The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine

NCT00724815

Phase 3 Completed 530 enrolled NuPathe Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This study was a randomized, parallel group, double-blind, placebo controlled design to compare the efficacy and tolerability of NP101 to a placebo iontophoretic transdermal patch. The primary objective of this study was to assess the proportion of subjects who were headache pain free at two hours after patch activation. Key secondary objectives included: 1. The proportion of subjects who were nausea free at two hours after patch activation. 2. The proportion of subjects who were photophobia free at two hours after patch activation. 3. The proportion of subjects who were phonophobia free at two hours after patch activation.

Timeline

Start
2009-01
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Sumatriptan Unknown Other

Indications